Table 1.
Demographic and clinical characteristics of the enrolled patients at baseline (T0) and at the end of the study (T1). CD: Crohn’s disease; UC: ulcerative colitis; BMI: body mass index; EIMs: extraintestinal manifestations; ISS: immunosuppressors.
| Characteristics (N = 58) | T0 | T1 | p-Value |
|---|---|---|---|
| Age (years), median [range] | 54 [18–78] | - | - |
| Female gender, n (%) | 36 (62) | - | - |
| CD, n (%) | 31 (53) | - | - |
| CD localization | |||
| L1, n (%) | 19/31 (61) | - | - |
| L2, n (%) | 4/31 (13) | - | - |
| L3, n (%) | 8/31 (26) | - | - |
| L4, n (%) | 0 | - | - |
| CD behaviour | |||
| B1, n (%) | 11/31 (35) | - | - |
| B2, n (%) | 16/31 (52) | - | - |
| B3, n (%) | 4/31 (13) | - | - |
| UC, n (%) | 27 (47) | - | - |
| UC extension | |||
| E1, n (%) | 2/27 (7) | - | - |
| E2, n (%) | 10/27 (37) | - | - |
| E3, n (%) | 15/27 (56) | - | - |
| Age at diagnosis | |||
| A1, n (%) | 5 (9) | - | - |
| A2, n (%) | 34 (58) | - | - |
| A3, n (%) | 19 (33) | - | - |
| Perianal Disease, n (%) | 11 (19) | ||
| BMI (kg/m2), median [range] | 25 [16–42] | 24 [15–41] | 0.09 |
| History of EIMs, n (%) | 19 (33) | - | - |
| History of steroid dependance/resistance, n (%) | 26 (45) | - | - |
| Clinically active disease, n (%) | 45 (78) | 22 (38) | <0.0001 |
| Current therapy with steroids, n (%) | 10 (17) | 4 (7) | 0.109 |
| Current therapy with biologic agents, n (%) | 36 (62) | 38 (66) | 0.77 |
| Current therapy with ISS, n (%) | 2 (3) | 2 (3) | >0.99 |
| Current therapy with mesalamine, n (%) | 37 (64) | 38 (66) | >0.99 |
| Charlson comorbidity index, median [range] | 1 [0–5] | 1 [0–5] | 0.25 |
| Psychiatric diseases, n (%) | 10 (17) | 12 (21) | 0.69 |
| Osteoarticular diseases, n (%) | 13 (22) | 15 (26) | 0.69 |
| Heart failure, n (%) | 1 (2) | 1 (2) | >0.99 |
| Pneumological diseases, n (%) | 5 (9) | 5 (9) | >0.99 |
| Neurodegenerative diseases, n (%) | 1 (2) | 1 (2) | >0.99 |
| Post-COVID fatigue, n (%) | 2 (3) | 2 (3) | >0.99 |